

**FRIULCHEM OBTAINS MARKETING AUTHORISATION
OF TWO PRODUCTS OF THE “HUMAN BUSINESS UNIT”:
IN VIETNAM FOR AN ANTI-DIABETIC DRUG IN ORAL FORM
IN SWITZERLAND FOR AN ANTIBIOTIC FOR UNCOMPLICATED ACUTE INFECTIONS OF
THE LOWER URINARY TRACTS**

**THE MARKETING WAS ENTRUSTED TO LEADING COMPANIES IN “GENERIC” DRUG
DISTRIBUTION**

**THE LAUNCH AND DISTRIBUTION WILL BE CARRIED OUT IN BOTH COUNTRIES IN THE
FIRST HALF OF 2020**

Milan, 19 February 2020 - Friulchem S.p.A. (AIM: FCM), innovative SME and one of the main Italian operators at international level in R&D and in the production on behalf of third parties (CDMO) of semi-finished and finished products containing pharmaceutical active ingredients, dietary supplements, specialising in particular in drug delivery for the veterinary sector, communicates that it has obtained the marketing authorisation for two products: in Vietnam, for an anti-diabetic drug in oral form, for the initial phase of the illness, distributed by a leading company in the supply of “generic drugs” imported to Europe; in Switzerland, for an antibiotic for treating uncomplicated acute infections of the lower urinary tracts, sold by a major multinational operating in all the main European countries, with whom Friulchem has been selling the same product in Germany for many years.

The agreements, both with a duration of 5 years, concern the licence for use of drugs by the leading companies in the distribution of generic drugs and whose ownership will remain with Friulchem.

The Company’s CEO Disma Giovanni Mazzola commented: *“We are happy to be able to announce that, once again, the dossiers of the Human division, related to the development strategy implemented before the listing, are continuing to make a positive contribution to Friulchem’s growth. Today the Company focuses more on the veterinary sector, which is the most interesting business for our future development”.*

The press release is available on the website <https://friulchem.com/it/media-relations/>

Friulchem (AIM:FCM), a company that has been operating in this sector for over 20 years, is today one of Italy’s leading CDMOs (*Contract Development Manufacturing Organisations*) operating internationally in the healthcare sector. It offers third-party research, development and manufacturing services for semi-finished and finished products containing both active pharmaceutical ingredients and food supplements. It primarily specialises in drug delivery systems for the veterinary sector, providing Friulchem’s trademark excellence,

as well as in the development of dossiers for generic medicines for human use. Friulchem is an innovative SME and B2B company which prides itself on its end-customer focus, and has deep Italian roots, thanks to its manufacturing facilities in Vivaro (Pordenone) and administrative headquarters in Milan. The Company is strongly oriented towards R&D activities and boasts established relationships with leading multinational companies in the pharmaceutical sector.

Common Shares ISIN: IT0005378457 - Friulchem Warrant ISIN: 2019-2022 IT0005378366

Friulchem S.p.A.

ir@friulchem.com

Tel: +39 02 36591450

Integrae SIM S.p.A. – Nominated Adviser

Giulia Mucciariello

info@integraesim.it

Tel: +39 02 87208720

CDR Communication - Investor and Media Relations

Silvia Di Rosa silvia.dirosa@cdr-communication.it

Marianna Tremolada marianna.tremolada@cdr-communication.it